Attorney Docket No. 24020-X Serial No. 09/871,809

CLAIMS

Pending completion of a personal interview with the Examiner, Applicant has not canceled, added, amended claims in this application. For the Examiner's convenience, Applicant attaches below a full set of pending claims 1-8, as they currently stand.

1. (Previously amended) A method of treatment of an individual suffering from a genetic disease resulting from an abnormal expression of genes caused by aberrant splicing in cells, the method comprising:

Administering to said cells of the individual or to tissue or organs of said individual comprising said cells, an effective amount of an alternative splicing factor (ASF), whereby said abnormal expression shifts towards normal expression of the gene thereby treating said disease.

- 2. (Original) A method according to Claim 1, wherein said disease is cystic fibrosis.
- 3. (Original) A method according to Claim 2, wherein the aberrant splicing is caused by a mutation 3849+10kb C->T.
 - 4. (Original) A method according to Claim 2, wherein the

Attorney Docket No. 24020-X Serial No. 09/871,809

aberrant splicing is caused by a mutation in the 5T allele.

- 5. (Previously amended) A method according to Claim 1, wherein the ASF is selected from the group consisting of:
 - (a) a member of the SR protein;
 - (b) heterogeneous nuclear ribonucleoprotein A1;
 - (c) viral factor E4-ORF3;
 - (d) viral factor E4-ORF6; and
 - (e) an agonist of any one of (i) to (iv).
- 6. (Original) A method according to Claim 1, wherein the ASF is administered to the cells or to the tissue or organs comprising the cells in a pharmaceutically acceptable vehicle.
- 7. (Original) A method according to Claim 6, wherein the ASF is administered directly to the cells or to the tissue or organ comprising the cells.
- 8. (Original) A method according to Claim 6, wherein the ASF is attached to a targeting moiety capable of binding specifically to said cells.

Attorney Docket No. 24020-X Serial No. 09/871,809

TELEPHONIC INTERVIEW SUMMARY

Applicant would like to take this opportunity to thank the Examiner for the courtesy extended during the brief telephonic interview held on September 17, 2003. In accordance with the discussions held during the interview, Applicant has not canceled, added, amended claims in this application, pending completion of a personal interview with the Examiner, which is to be completed after September 30, 2003 at the request of the Examiner.